|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:ranitidine
|
|
gptkbp:activities
|
inhibits gastric acid secretion
|
|
gptkbp:approves
|
gptkb:1988
gptkb:FDA
|
|
gptkbp:brand
|
Axid
|
|
gptkbp:category
|
B
|
|
gptkbp:class
|
H2 receptor antagonist
|
|
gptkbp:clinical_trial
|
Phase III trials
maintenance therapy for duodenal ulcers
short-term treatment of active duodenal ulcers
treatment of erosive esophagitis
|
|
gptkbp:contraindication
|
severe renal impairment
hypersensitivity to nizatidine
|
|
gptkbp:developed_by
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
gptkb:beer
oral solution
injectable solution
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
nizatidine
|
|
gptkbp:indication
|
prevention of ulcers
treatment of Zollinger-Ellison syndrome
|
|
gptkbp:ingredients
|
C12 H21 N5 O2 S
|
|
gptkbp:interacts_with
|
gptkb:ketoconazole
gptkb:beer
gptkb:theophylline
gptkb:warfarin
|
|
gptkbp:is_available_on
|
gptkb:product
gptkb:tablet
|
|
gptkbp:is_used_for
|
treatment of gastroesophageal reflux disease (GERD)
treatment of ulcers
|
|
gptkbp:lifespan
|
1-2 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
gptkb:Europe
gptkb:Australia
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:related_to
|
gptkb:ranitidine
gptkb:cimetidine
gptkb:famotidine
histamine H2 receptor antagonists
|
|
gptkbp:side_effect
|
dizziness
headache
nausea
diarrhea
constipation
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:type_of
|
76963-41-2
|